<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yan L</submitter><funding>The key project of food safety of the Science and Technology Ministry of China</funding><funding>National Natural Science Foundation of China</funding><pagination>e9306</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7350924</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8</volume><pubmed_abstract>Added risk portended by diabetes in addition to hypertension has been related to an amplification of endothelial dysfunction. β-blockers are widely used for cardiovascular diseases and improve the endothelial function compared with a placebo. However, the effect of β-blockers on the endothelial progenitor cells (EPCs) function in diabetes is still unknown. Five β-blockers (metoprolol, atenolol, propranolol, bisoprolol, and nebivolol) were tested in EPC functional screening. Metoprolol improved EPC function significantly among the five β-blockers and was chosen for the &lt;i>in vivo&lt;/i> tests in STZ induced diabetic mice. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements were performed using the Endo-PAT2000 device in diabetic patients. Metoprolol, but not other β-blockers</pubmed_abstract><journal>PeerJ</journal><pubmed_title>Metoprolol rescues endothelial progenitor cell dysfunction in diabetes.</pubmed_title><pmcid>PMC7350924</pmcid><funding_grant_id>81703627</funding_grant_id><funding_grant_id>81872660</funding_grant_id><funding_grant_id>2017YFC1600204</funding_grant_id><funding_grant_id>81803643</funding_grant_id><pubmed_authors>Li JF</pubmed_authors><pubmed_authors>Yan L</pubmed_authors><pubmed_authors>Deng YP</pubmed_authors><pubmed_authors>Qing TL</pubmed_authors><pubmed_authors>Dai XY</pubmed_authors><pubmed_authors>Dong YF</pubmed_authors><pubmed_authors>Chen JK</pubmed_authors><pubmed_authors>Han X</pubmed_authors><pubmed_authors>Tian YJ</pubmed_authors><pubmed_authors>Gao FY</pubmed_authors><pubmed_authors>Zhu JB</pubmed_authors><pubmed_authors>Shi WJ</pubmed_authors><pubmed_authors>Zhang XF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Metoprolol rescues endothelial progenitor cell dysfunction in diabetes.</name><description>Added risk portended by diabetes in addition to hypertension has been related to an amplification of endothelial dysfunction. β-blockers are widely used for cardiovascular diseases and improve the endothelial function compared with a placebo. However, the effect of β-blockers on the endothelial progenitor cells (EPCs) function in diabetes is still unknown. Five β-blockers (metoprolol, atenolol, propranolol, bisoprolol, and nebivolol) were tested in EPC functional screening. Metoprolol improved EPC function significantly among the five β-blockers and was chosen for the &lt;i>in vivo&lt;/i> tests in STZ induced diabetic mice. Reactive hyperemia peripheral arterial tonometry (RH-PAT) measurements were performed using the Endo-PAT2000 device in diabetic patients. Metoprolol, but not other β-blockers</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2025-04-19T21:09:28.214Z</modification><creation>2025-02-19T00:51:41.389Z</creation></dates><accession>S-EPMC7350924</accession><cross_references><pubmed>32704438</pubmed><doi>10.7717/peerj.9306</doi></cross_references></HashMap>